Description
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-2; it exhibits anti-inflammatory, analgesic, antipyretic, neuroprotective, antioxidative, and hepatoprotective activities. In animal models of Parkinson’s disease, meloxicam inhibits MPTP-induced motor dysfunction and increases levels of tyrosine hydroxylase. In animal models of CCL(4)-induced liver damage, meloxicam increases levels of superoxide dismutase, catalase, and glutathione-S-transferase and decreases levels of malondialdehyde, prostaglandin E2 (PGE2), and activated caspase 3.
References
Tasaki Y, Yamamoto J, Omura T, et al. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model. Neurosci Lett. 2012 Jul 11;521(1):15-9. PMID: 22617635.
Edfawy M, Hassan MH, Mansour A, et al. Meloxicam modulates oxidative stress status, inhibits prostaglandin E2, and abrogates apoptosis in carbon tetrachloride-induced rat hepatic injury. Int J Toxicol. 2012 Jun;31(3):276-86. PMID: 22556387.
Noble S, Balfour JA. Meloxicam. Drugs. 1996 Mar;51(3):424-32. PMID: 8882380.
Malreddy PR, Coetzee JF, Kukanich B, Gehring R. Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. J Vet Pharmacol Ther. 2013 Feb;36(1):14-20. PMID: 22372845.
